Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01483846 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers
A Phase 1 study, sponsored by VistaGen Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01483846 is a Phase 1 study that has completed, run by VistaGen Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT01483846, a Phase 1 study, has completed, sponsored by VistaGen Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase 1b study involving multiple oral doses of AV-101 in healthy male and female subjects. The safety, pharmacokinetics, and antihyperalgesic effect of AV-101 on capsaicin-induced hyperalgesia will be assessed.
Interventions
- DRUG Placebo
- DRUG AV-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01483846
The ClinicalTrials.gov registry entry for NCT01483846 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VistaGen Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01483846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01483846 about?
NCT01483846 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers". This is a Phase 1b study involving multiple oral doses of AV-101 in healthy male and female subjects. The safety, pharmacokinetics, and antihyperalgesic effect of AV-101 on capsaicin-induced hyperalgesia will be assessed.
What is the current status of trial NCT01483846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2011-12. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01483846?
The interventions under investigation include: Placebo (DRUG), AV-101 (DRUG).
Who is sponsoring clinical trial NCT01483846?
This trial is sponsored by VistaGen Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.